| Literature DB >> 27382292 |
Suliman Khan1, Ghulam Nabi2, Muhammad Naeem3, Liaqat Ali4, Peter A Silburn5, George D Mellick1.
Abstract
INTRODUCTION: Parkinson's disease (PD) occurs in all races and cultures, and population-related differences in frequency may provide etiological clues. The present study was designed to explore the prevalence of PD and Parkinsonism in Pakistan, the world's sixth most populous country, for which no published prevalence data are available.Entities:
Keywords: Parkinsonism; Parkinson’s disease; door-to-door survey
Year: 2016 PMID: 27382292 PMCID: PMC4922770 DOI: 10.2147/NDT.S86329
Source DB: PubMed Journal: Neuropsychiatr Dis Treat ISSN: 1176-6328 Impact factor: 2.570
Figure 1The age-specific prevalence of iPD in Pakistan as assessed by our door-to-door survey.
Abbreviation: iPD, idiopathic Parkinson’s disease.
Age- and sex-specific extrapolated prevalence of all types of Parkinsonism and Parkinson’s disease
| Age group (years) | Phase I
| Phase II
| Phase III prevalence estimates
| |||||
|---|---|---|---|---|---|---|---|---|
| iPD
| All types of Parkinsonism
| |||||||
| Number surveyed (A) | Number screened positive (B) | Number evaluated (C) | Confirmed Parkinsonism (N) | Number diagnosed (N) | Extrapolated prevalence (%) | Number diagnosed (N) | Extrapolated prevalence (%) | |
| 50–54 | 1,049 | 38 | 24 | 1 | 1 | 0.15 | 1 | 0.1 |
| 55–59 | 796 | 37 | 33 | 0 | 0 | 0 | 0 | 0 |
| 60–64 | 770 | 39 | 32 | 1 | 1 | 0.16 | 1 | 0.16 |
| 65–69 | 392 | 63 | 46 | 2 | 2 | 0.7 | 2 | 0.7 |
| 70–74 | 237 | 52 | 27 | 2 | 2 | 1.6 | 2 | 1.6 |
| 75–79 | 194 | 33 | 24 | 4 | 3 | 2.0 | 4 | 2.8 |
| ≥80 | 277 | 47 | 28 | 4 | 2 | 1.2 | 4 | 2.5 |
| Total | 3,715 | 303 | 205 | 14 | 11 | 0.43 | 14 | 0.55 |
| 50 years and above | ||||||||
| Males | 2,288 | 218 | 144 | 9 | 8 | 0.53 | 9 | 0.61 |
| Females | 1,427 | 85 | 61 | 5 | 3 | 0.3 | 5 | 0.48 |
| All | 3,715 | 303 | 205 | 14 | 11 | 0.43 | 14 | 0.55 |
| 65 years and above | ||||||||
| Males | 732 | 141 | 88 | 7 | 6 | 1.32 | 7 | 1.5 |
| Females | 369 | 54 | 36 | 5 | 3 | 1.31 | 5 | 1.9 |
| All | 1,101 | 195 | 124 | 12 | 9 | 1.28 | 12 | 1.7 |
| Standardized iPD prevalence (%) | 50 years and above | 95% CI | 65 years and above | 95% CI | ||||
| 0.66 | 0.4–0.9 | 1.33 | 0.7–2.1 | |||||
Notes: Age standardized to USA population in 2000. (A) Number of individuals by age and sex (B) Number of individuals with positive screening. (C) Number of individuals evaluated in phase.
Abbreviations: iPD, idiopathic Parkinson’s disease; N, number of individuals affected; CI, confidence interval.
Number of respondents and nonrespondents in Phase II
| Phase II
| |||||
|---|---|---|---|---|---|
| Number of respondents | Number of nonrespondents | N | Mean age (years) | ||
| Sex | |||||
| Males | 144 | 74 | 218 | 0.3 | 68.1 |
| Females | 61 | 24 | 85 | – | 66.8 |
| Location | |||||
| Lower Dir | 112 | 53 | 165 | 0.9 | 66.2 |
| Malakand | 93 | 45 | 138 | – | 69.5 |
| Mean age (years) | 67 | 69 | 0.1 | 67.7 | |
Abbreviation: N, number of individuals.
Figure 2Parkinsonism and self-reported non-Parkinsonism complications.
Number of cases identified by age, sex, and location of all types of Parkinsonism and iPD in Phase III
| Age group | All types of Parkinsonism
| iPD
| ||||
|---|---|---|---|---|---|---|
| N | Extrapolated prevalence (%) | 95% CI | N | Extrapolated prevalence (%) | 95% CI | |
| Male | 9 | 0.61 | 0.28–0.92 | 8 | 0.53 | 0.27–0.84 |
| Female | 5 | 0.48 | 0.12–0.84 | 3 | 0.3 | 0.11–0.72 |
| Total | 14 | 0.55 | 0.3–0.8 | 11 | 0.43 | 0.22–0.64 |
| Male | 7 | 1.5 | 0.6–2.3 | 6 | 1.32 | 0.6–2.3 |
| Female | 5 | 2 | 0.5–3.4 | 3 | 1.21 | 0.4–2.7 |
| Total | 12 | 1.7 | 0.9–2.46 | 9 | 1.28 | 0.6–1.94 |
| lower Dir | 6 | 1.65 | 0.57–2.7 | 4 | 1.12 | 0.22–1.98 |
| Malakand | 6 | 1.73 | 0.65–2.8 | 5 | 1.45 | 0.46–2.44 |
Abbreviations: CI, confidence interval; iPD, idiopathic Parkinson’s disease; N, number of cases.
Figure 3hospital-based healthy individuals’ responses to each question in the screening instrument.